Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2017-05-16 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K 05.16.17 BR LEASE
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 17, 2017, reporting the entry into a new lease agreement and termination of an existing lease. It details material definitive agreements related to office leases, including terms and rent amounts. There are no financial statements or earnings data, no management discussion or analysis, no voting results, no audit information, and no other report types. The content is about a material contract event, which is typically covered under regulatory filings. The document length is 3848 characters, which is relatively short and consistent with an 8-K current report. Therefore, this is a Regulatory Filing (RNS) rather than a full report or announcement of a report publication.
2017-05-16 English
10-Q 03.31.17
Interim / Quarterly Report Q1 2017
2017-05-15 English
DEFA14A 05.09.17
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or related materials filed with the SEC. It discusses proxy solicitation for a shareholder meeting, including voting instructions and details about a proposed transaction (sale of subsidiary interest). It references the proxy statement and urges shareholders to read it. The document is not the proxy statement itself but additional materials related to the proxy solicitation. The document is not a full financial report, earnings release, or management discussion. It is clearly related to proxy solicitation and shareholder voting information. Therefore, the filing type corresponds to 'DEF 14A' which covers remuneration and proxy statements and related materials. The document is 8231 characters, which is substantive and not just a brief announcement, supporting classification as DEF 14A rather than RPA or RNS.
2017-05-09 English
DEFA14A 05.05.17
Remuneration Information Classification · 100% confidence The document is titled 'SCHEDULE 14A' and is identified as a 'Definitive Additional Materials' to a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It references an annual meeting of stockholders and provides corrections, clarifications, and additions to disclosures in the Proxy Statement, specifically related to a sale proposal and valuation analyses. The content is clearly supplemental to a Proxy Statement and not the Proxy Statement itself. Proxy Statements and related materials fall under the category of Proxy Solicitation & Information Statement filings. The document is not a full Annual Report, Earnings Release, or any other financial report type, but rather additional proxy materials. Therefore, the correct classification is 'DEF 14A' which corresponds to Remuneration Information and Proxy Statements filings, specifically Schedule 14A filings.
2017-05-05 English
DEFA14A 05.01.17
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or related materials filed pursuant to the Securities Exchange Act of 1934. It contains detailed information about a proposed transaction (sale of a majority interest in a subsidiary), communications to employees about the transaction, and instructions for shareholders regarding the proxy vote. The document is explicitly labeled as "Definitive Additional Materials" related to a proxy solicitation. It is not a full annual report, earnings release, or financial statement, but rather materials sent to shareholders to provide information and request votes for a meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (15,000 characters) and content confirm it is not a brief announcement or a certification but substantive proxy materials.
2017-05-01 English
DEFA14A PRESENTATION 042717
Proxy Solicitation & Information Statement Classification · 95% confidence The document is identified as a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to a proxy statement for Caladrius Biosciences, Inc. The content includes presentation information for an investor day and references an Interest Purchase Agreement. Proxy statements and related materials are classified under Proxy Solicitation & Information Statement (PSI). The document length is short (2491 characters), but it is not merely an announcement of a report; it is additional proxy materials. Therefore, the correct classification is PSI with high confidence.
2017-04-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.